Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biotechnology innovator developing intranasal immunotherapies for neurodegenerative and inflammatory diseases. This page provides centralized access to official corporate announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TLSA's novel drug delivery platform, including progress with intranasal foralumab and other candidates targeting multiple sclerosis, Alzheimer's, and autoimmune conditions. The repository includes press releases on FDA communications, partnership announcements, and peer-reviewed research findings.
Key content categories include clinical trial milestones, intellectual property updates, executive leadership changes, and financial performance reports. All materials are sourced directly from the company and verified financial news outlets to ensure accuracy.
Bookmark this page for streamlined tracking of TLSA's progress in advancing non-invasive immunotherapy solutions. Check regularly for updates on groundbreaking approaches to modulating immune responses through nasal administration.
Tiziana Life Sciences (NASDAQ:TLSA) has initiated dosing in its Phase 2a clinical trial of intranasal foralumab for Multiple System Atrophy (MSA) at Brigham and Women's Hospital in Boston. The six-month open-label study will evaluate foralumab's potential to reduce neuroinflammation in MSA patients through a novel nasal delivery system.
MSA is a rare neurodegenerative disorder affecting 15,000-50,000 people in the United States, with no FDA-approved treatments to alter disease progression. The trial (NCT06868628) will involve eight dosing cycles to assess the therapy's ability to slow disease progression and enhance quality of life through regulatory T cell engagement.
Tiziana Life Sciences (NASDAQ:TLSA) has received FDA approval for its Phase 2a Investigational New Drug (IND) application to study intranasal foralumab in Multiple System Atrophy (MSA) patients. The six-month, open-label clinical trial will evaluate foralumab, a fully human anti-CD3 monoclonal antibody, for its effects on microglial activation, clinical outcomes, and safety.
MSA is a rare, rapidly progressive neurodegenerative disorder with no FDA-approved treatments. The disease affects 1.9-4.9 per 100,000 people worldwide, with a median survival of 6-9 years. The trial (NCT06868628) will administer foralumab via nasal spray in eight 3-week dosing cycles, targeting T-cell mediated neuroinflammation.
Tiziana Life Sciences (NASDAQ:TLSA) has reported promising immunologic findings from treating a moderate Alzheimer's Disease patient with intranasal foralumab, their lead immunomodulation therapy. The analysis revealed significant immune modulatory effects in white blood cells, including changes in CD4 cells, CD8 cells, and monocytes.
Key findings include a marked reduction in brain inflammation confirmed by microglia PET scans and an unexpected increase in phagocytosis markers in classical monocytes, suggesting potential for enhanced amyloid plaque clearance. The treatment was well-tolerated with no side effects, and the patient will continue therapy for an additional 6 months.
Tiziana Life Sciences (NASDAQ: TLSA) has showcased promising developments in their intranasal foralumab treatment for moderate Alzheimer's disease through a national radio interview. The treatment, a fully human anti-CD3 monoclonal antibody administered as a nasal spray, targets brain inflammation associated with Alzheimer's progression. Dr. Howard Weiner highlighted remarkable results from the first patient, Joe Walsh, at Brigham and Women's Hospital in Boston. According to Walsh's wife Karen, the treatment has led to noticeable improvements in his social engagement and overall condition. The case represents an encouraging advancement in Alzheimer's treatment, particularly in addressing brain inflammation as a key factor in disease progression.
Tiziana Life Sciences (NASDAQ: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone has increased his stake in the company through the purchase of 15,000 common shares at $1.55 per share. Following this transaction, Cerrone's total holdings have reached 43,252,143 common shares, representing 37.02% of the company's issued share capital. Tiziana is developing immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody.
Tiziana Life Sciences (NASDAQ: TLSA) has announced positive results from a clinical study of nasal foralumab in treating non-active secondary progressive multiple sclerosis (na-SPMS). The study involved 10 patients who were treated for a minimum of six months, with key findings including:
- No serious treatment-related adverse events reported
- Stabilization of Expanded Disability Status Scale (EDSS) scores in all patients
- Improvement in fatigue symptoms in 6 out of 10 patients
- Significant reductions in microglial activation at six months (p<0.05)
- No new T2 lesions observed on MRI
- Increased regulatory T cells and TGFβ expression
The company has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial with expected top-line data by the end of 2025. The treatment represents a novel approach for na-SPMS patients who currently have limited treatment options.
FAQ
What is the current stock price of Tiziana Life Sciences Com (TLSA)?
What is the market cap of Tiziana Life Sciences Com (TLSA)?
